Blue Earth Diagnostics Limited, a leading innovator in the field of molecular imaging, is headquartered in Great Britain. Founded in 2014, the company has rapidly established itself as a key player in the development of diagnostic imaging agents, particularly for prostate cancer. With a focus on PET (positron emission tomography) imaging, Blue Earth Diagnostics offers unique radiopharmaceuticals that enhance the detection and management of cancer. Their flagship product, Axumin, is notable for its ability to detect prostate cancer recurrence with high specificity and sensitivity. The company has achieved significant milestones, including regulatory approvals in various regions, solidifying its position in the global market. Blue Earth Diagnostics continues to advance the field of oncology diagnostics, contributing to improved patient outcomes through innovative imaging solutions.
We don't have data for Blue Earth Diagnostics Limited, but we can show you information about their parent organization instead.
View parent company